Idorsia Ltd

Simcere Pharmaceuticals has received approval from China's National Medical Products Administration for QUVIVIQ (daridorexant) to treat adult insomnia patients with difficulty falling asleep and/or maintaining sleep.

New clinical data reveals daridorexant effectively reduces wakefulness throughout the night while improving next-morning sleepiness and daytime functioning in patients with chronic insomnia disorder.

Aprocitentan, a dual endothelin receptor antagonist, demonstrated clinically meaningful and sustained blood pressure reductions in Black patients with resistant hypertension when added to existing antihypertensive regimens.

The US FDA has eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirement for TRYVIO (aprocitentan), determining that standard labeling is sufficient to communicate safety information.

• Owkin has initiated ATLANTIS, a comprehensive patient data mining program partnering with 20 leading healthcare institutions across seven countries, set to conclude by May 2025. • The project will analyze data across 11 therapeutic areas, including seven oncology programs, three immunology and inflammation conditions, and Alzheimer's disease, utilizing Owkin's AI platform Owkin K. • This initiative aims to break down data silos by integrating diverse medical data sources, including health records, imaging, and diagnostic results, to accelerate drug discovery and development.

Viatris has secured exclusive global rights to cenerimod, a novel oral S1P1 receptor modulator, through a $10 million upfront payment to Nxera Pharma for Japan and APAC territories.

The US Defense Health Agency partners with GCAR to conduct a Phase II platform trial testing three different pharmacotherapies for PTSD in active soldiers and veterans.

The FDA approved an expanded indication for subcutaneous furosemide injection for heart failure patients, offering a convenient self-administration option.